Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenzilumab - Humanigen

Drug Profile

Lenzilumab - Humanigen

Alternative Names: KB-003

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Developer Humanigen; KaloBios Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Drug hypersensitivity
  • Phase I Chronic myelomonocytic leukaemia
  • Preclinical Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
  • Research Solid tumours
  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 09 Oct 2019 Humanigen plans a phase II trial for Graft versus host disease in United Kingdom
  • 01 Oct 2019 Preclinical trials in Graft-versus-host disease in United Kingdom (unspecified route), before October 2019
  • 22 Jul 2019 Humanigen in-licenses technology used to prevent graft versus host disease from University of Zurich
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top